title: Effect of lisinopril on rat liver tissues in L-NAME induced hypertension model.
abstract: N(G)-Nitro-L-arginine methyl ester hydrochloride (L-NAME) is a non-specific nitric oxide (NO) inhibitor and it has been used to eliminate the role of NO in many studies like animal models for hypertension. In this study, we aimed to investigate whether lisinopril treatment has any biochemical and/or histopathological effect on rat liver tissue in a L-NAME-induced hypertension model. Forty-eight 6-weeks-old male Spraque-Dawley rats were used in the study. The animals used in the study were randomly divided into four equal groups. To induce hypertension, L-NAME was added to drinking water at a concentration of 600 mg/l and each rat was given 75 mg/kg/day of L-NAME for 6 weeks. Tail cuff systolic blood pressure (SBP) was measured at first, third, and sixth weeks. There was a significant difference between the experiment groups and controls. In only lisinopril given and L-NAME plus lisinopril administered groups, each rat was given 10 mg/kg of lisinopril for 6 weeks. At the end of the study, the animals were sacrificed. Blood and tissue samples were collected for biochemical and histopathological analysis. It has been observed that mean NO level was significantly decreased in L-NAME given group (p<0.05). Mean ALT levels were significantly increased in lisinopril and L-NAME plus lisinopril given groups, when compared with the control group (p<0.05). AST levels were in normal range in all groups (p>0.05). Hepatocyte degeneration was prominent in lisinopril given group, whereas mononuclear cell infiltration was significant in L-NAME given groups. Although the beneficial effects in L-NAME-induced hypertension treatment, lisinopril can lead to some unexpected results like hepatocyte degeneration, serum enzyme level elevation, and slight mononuclear cell infiltration.
authors.affiliation: Department of Histology and Embryology, Suleyman Demirel University School of Medicine, Isparta, Turkey. gokcimen@med.sdu.edu.tr
authors.forename: Alpaslan
authors.initials: A
authors.lastname: Gokcimen
authors.forename: Ahmet
authors.initials: A
authors.lastname: Kocak
authors.forename: Serkan
authors.initials: S
authors.lastname: Kilbas
authors.forename: Dilek
authors.initials: D
authors.lastname: Bayram
authors.forename: Aynur
authors.initials: A
authors.lastname: Kilbas
authors.forename: Abdullah
authors.initials: A
authors.lastname: Cim
authors.forename: Cem
authors.initials: C
authors.lastname: Kockar
authors.forename: Suleyman
authors.initials: S
authors.lastname: Kutluhan
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000502:physiology; D004791:Enzyme Inhibitors / Q000633:toxicity*; D006973:Hypertension / Q000139:chemically induced* / Q000188:drug therapy / Q000378:metabolism; D017706:Lisinopril / Q000494:pharmacology* / Q000627:therapeutic use; D008099:Liver / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D019331:NG-Nitroarginine Methyl Ester / Q000633:toxicity*; D009569:Nitric Oxide / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D000959:Antihypertensive Agents; D004791:Enzyme Inhibitors; D009569:Nitric Oxide; D017706:Lisinopril; D019331:NG-Nitroarginine Methyl Ester